{"entity":{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","aka":["Perlmutter Cancer Center","NYU Cancer Institute"],"tldr":"NYU's cancer centre, comprehensive since 2019, known for melanoma immunotherapy, RAS and SHP2 biology, and early deep-learning pathology.","summary":"NCI-designated since the 1970s and comprehensive since 2019, Perlmutter Cancer Center spans NYU Langone's Manhattan, Brooklyn and Long Island hospitals. Its melanoma programme (Jeffrey Weber, Iman Osman, Anna Pavlick) led adjuvant nivolumab trials; Benjamin Neel, the director, discovered the phosphatase SHP2 (PTPN11), now a drug target in RAS-driven cancers; Dafna Bar-Sagi's laboratory defined how KRAS-mutant pancreatic cancers scavenge nutrients. Aristotelis Tsirigos's 2018 study of deep learning on lung cancer histology slides was an early landmark in computational pathology. Michele Pagano's work on ubiquitin ligases underpins targeted protein degradation.","asOf":"2026-09-09","links":[{"label":"Perlmutter Cancer Center","url":"https://nyulangone.org/locations/perlmutter-cancer-center"},{"label":"Clinical trials","url":"https://nyulangone.org/locations/perlmutter-cancer-center/clinical-trials"}],"tags":[],"related":[],"cancers":["melanoma","pancreatic","nsclc"],"sections":["immunotherapy","ai-computation"],"technologies":["digital-pathology-ai","protac-degrader","gamma-knife","radiosurgery-srs"],"targets":["kras","pd1"],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["arjun-balar","douglas-levine","jeffrey-weber"],"bottlenecks":["b-undruggable-targets"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York, NY","country":"US","lat":40.742,"lng":-73.974,"institutionType":"cancer-center","website":"https://nyulangone.org/locations/perlmutter-cancer-center","nci":"comprehensive","university":"New York University","programs":["Melanoma immunotherapy","RAS and SHP2 biology","Computational pathology"]},"route":"/institutions/nyu-perlmutter/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/"},{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"person":[{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","route":"/people/arjun-balar/"},{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","route":"/people/douglas-levine/"},{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"paper":[{"id":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","kind":"paper","name":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","route":"/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/"},{"id":"paper-gonda-precede-consortium-recommendations-gastroenterology-2021","kind":"paper","name":"Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium","route":"/key-papers/paper-gonda-precede-consortium-recommendations-gastroenterology-2021/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}]}}